Literature DB >> 23861036

B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.

Erika Falisi1, Elisabetta Novella, Carlo Visco, Nicola Guercini, Francesco Maura, Ilaria Giaretta, Fabrizio Pomponi, Ilaria Nichele, Silvia Finotto, Annamaria Montaldi, Antonino Neri, Francesco Rodeghiero.   

Abstract

Trisomy 12 (+12) is the third most frequent cytogenetic aberration in chronic lymphocytic leukaemia (CLL) retrievable both as the sole chromosomal abnormality or in association with additional alterations. NOTCH1 mutations are known to be more prevalent among +12 patients, whereas mutations of FBXW7, a gene involved in NOTCH1 degradation, that lead to the constitutional activation of NOTCH1 have not been investigated in this setting. We analyzed a unicentric cohort of 44 +12 patients with CLL for mutations of TP53, NOTCH1 and FBXW7 genes, and we correlated them with B-cell receptor (BCR) configurations. FBXW7, TP53 and NOTCH1 mutations were identified in 4.5%, 6.8% and 18.2% of patients, respectively. FBXW7 and NOTCH1 mutations appeared in a mutually exclusive fashion, suggesting that both aberrations might affect the same biological pathway. We found that 44.1% of +12 CLL patients had stereotyped B-cell receptors, which is significantly higher than that observed in patients with CLL and no +12 (27%, p = 0.01). Subsets #1, #8, #10, #28 and #59 were the most represented stereotyped patterns, and IGHV4-39*01 was the gene configuration most commonly used. There was a significantly higher risk for Richter's syndrome (RS) transformation in patients with NOTCH1 or FBXW7 mutations, with four of the seven (57%) patients developing RS and characterized at least by one of the two abnormalities. These observations suggest that, similarly to the aberrations of NOTCH1, FBXW7 gene mutations may also result in cell proliferation and evasion from apoptosis in patients with +12 CLL. Together with the extremely high frequency of stereotyped BCRs and RS transformation, these abnormalities appear to cluster in these CLL patients with additional chromosome 12, suggesting a connection with the prognosis of the disease.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  FBXW7; NOTCH1; TP53; chronic lymphocytic leukaemia; stereotyped BCR

Mesh:

Substances:

Year:  2013        PMID: 23861036     DOI: 10.1002/hon.2086

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  12 in total

1.  Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.

Authors:  Omar Perbellini; Erika Falisi; Ilaria Giaretta; Elisa Boscaro; Elisabetta Novella; Monica Facco; Stefania Fortuna; Silvia Finotto; Eliana Amati; Francesco Maniscalco; Anna Montaldi; Alberta Alghisi; Fiorenza Aprili; Laura Bonaldi; Rossella Paolini; Maria Teresa Scupoli; Livio Trentin; Achille Ambrosetti; Gianpietro Semenzato; Giovanni Pizzolo; Francesco Rodeghiero; Carlo Visco
Journal:  Haematologica       Date:  2014-01-10       Impact factor: 9.941

2.  Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.

Authors:  Yohei Chiba; Seiya Sato; Hiroaki Itamochi; Yasuko Suga; Tomoyuki Fukagawa; Nao Oumi; Tetsuro Oishi; Tasuku Harada; Tamotsu Sugai; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-11-26       Impact factor: 4.174

3.  Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Authors:  Paolo Strati; Lynne V Abruzzo; William G Wierda; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-11

4.  CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Fiona Pui San Liaw; Lai Ching Lau; Alvin Soon Tiong Lim; Tse Hui Lim; Geok Yee Lee; Sim Leng Tien
Journal:  Int J Hematol       Date:  2014-10-10       Impact factor: 2.490

Review 5.  Prognostic Factors in the Era of Targeted Therapies in CLL.

Authors:  Prajwal Boddu; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

6.  A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia.

Authors:  Paulo Vidal Campregher; Roberta Cardoso Petroni; Nair Hideko Muto; Roberta Sitnik; Flavia Pereira de Carvalho; Nydia Strachman Bacal; Elvira Deolinda Rodrigues Pereira Velloso; Gislaine Borba Oliveira; João Renato Rebello Pinho; Davi Coe Torres; Marcela Braga Mansur; Rocio Hassan; Irene Gyongyvér Heidemarie Lorand-Metze; Carlos Sérgio Chiattone; Nelson Hamerschlak; Cristovão Luis Pitangueira Mangueira
Journal:  Biomed Res Int       Date:  2016-12-15       Impact factor: 3.411

Review 7.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

8.  B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib.

Authors:  Krzysztof Lewandowski; Michał Gniot; Maria Lewandowska; Anna Wache; Błażej Ratajczak; Anna Czyż; Małgorzata Jarmuż-Szymczak; Mieczysław Komarnicki
Journal:  Case Rep Med       Date:  2016-03-03

9.  Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Authors:  Laura Lupini; Cristian Bassi; Jitka Mlcochova; Gentian Musa; Marta Russo; Petra Vychytilova-Faltejskova; Marek Svoboda; Silvia Sabbioni; Radim Nemecek; Ondrej Slaby; Massimo Negrini
Journal:  BMC Cancer       Date:  2015-10-27       Impact factor: 4.430

Review 10.  NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.

Authors:  Emanuela Rosati; Stefano Baldoni; Filomena De Falco; Beatrice Del Papa; Erica Dorillo; Chiara Rompietti; Elisa Albi; Franca Falzetti; Mauro Di Ianni; Paolo Sportoletti
Journal:  Front Oncol       Date:  2018-06-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.